Published on Microbicide Trials Network (http://www.mtnstopshiv.org)

Home > MTN-001

MTN-001

A Phase II trial directly comparing the tablet and vaginal gel formulations of the antiretroviral drug tenofovir, looking at women’s adherence to and acceptance of three daily regimens – tenofovir gel, tenofovir tablet and the two together – and how the drug is absorbed by and distributed in the body.
 
See
Study comparing tenofovir gel and oral tablet finds gel provides more drug to tissue [1]
Feb 28, 2011
  
HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study [2]
Jul 9, 2008
 
MTN-001 Backgrounder [3]
   
MTN-001 Fact Sheet [4]
  
MTN-001 Q&A [5]
 
See Also
MTN-001 Study Protocol [6]
Printer-friendly version [7]
Source URL: http://www.mtnstopshiv.org/news/studies/mtn001

Links:
[1] http://www.mtnstopshiv.org/node/2929
[2] http://www.mtnstopshiv.org/node/462
[3] http://www.mtnstopshiv.org/news/studies/mtn001/backgrounder
[4] http://www.mtnstopshiv.org/news/studies/mtn001/facts
[5] http://www.mtnstopshiv.org/news/studies/mtn001/qa
[6] http://www.mtnstopshiv.org/sites/default/files/attachments/MTN-001%20Final%20Version%202%200%2003Sept08.pdf
[7] http://www.mtnstopshiv.org/print/817

Media Contacts:

Lisa Rossi -- Office: +1 412 641-8940 -- Mobile: +1 412 916-3315 -- Email: rossil@upmc.edu

Clare Collins -- Office: +1 412 641-7299 -- Mobile: +1 412 770-8643 -- Email: collcx@upmc.edu